Baxter International

BAX · NYSE

$24.51−$0.48 (−1.92%)TodayMarket closed ·
Prev close $24.99

About BAX

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 37,500 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

Employees
37,500
Headquarters
Deerfield, Illinois
Listed
May 15, 1961
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
baxter.com

Leadership

Baxter International executives
NameTitleSince
D. Brent Shafer—2022
Andrew Hider—2025
Joel Grade——
Jeanne Mason——
David Rosenbloom——
James Borzi——
Reazur Rasul——
Nancy Schlichting——
Michael McDonnell——
William Ampofo——
Jeffrey Craig——
Amy Mcbride-Wendell——
Patricia Morrison——
Stephen Oesterle——
Stephen Rusckowski——
Catherine Smith——
David Wilkes——
Clare Trachtman—2024

Revenue by product and region

Fiscal year ended Dec 31, 2025: $11.24B total revenue

By region

  • United States$6.12B54.4%
  • Non-US$5.12B45.6%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Baxter International suppliers and customers
CompanyRelationshipCorrelation
Ligand Pharmaceuticals LGNDSupplier and customer0.42
Live Nation Entertainment, Inc. LYVSupplier0.39
Perella Weinberg A PWPSupplier0.36
Societede la Tour Eiffel EIFF.PASupplier0.35
AQ Group AB (publ) AQ.STSupplier0.33
InfuSystem INFUCustomer0.33
bioMerieux BIM.PASupplier and customer0.32
bioMérieux S.A. BMXMFSupplier0.31
Premier A PINCSupplier0.30
Benchmark Electronics, Inc. BHESupplier0.30

Similar companies

Companies in the same industry as Baxter International

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.